3 259

Cited 16 times in

The increase in abdominal subcutaneous fat depot is an independent factor to determine the glycemic control after rosiglitazone treatment

Authors
 Soo-Kyung Kim  ;  Kyu-Yeon Hur  ;  Bong-Soo Cha  ;  Hyun-Chul Lee  ;  Sung-Kil Lim  ;  Yong-Wook Cho  ;  Seok-Won Park  ;  Chul-Woo Ahn  ;  Wan-Sub Shim  ;  Hae-Jin Kim 
Citation
 EUROPEAN JOURNAL OF ENDOCRINOLOGY, Vol.157(2) : 167-174, 2007 
Journal Title
 EUROPEAN JOURNAL OF ENDOCRINOLOGY 
ISSN
 0804-4643 
Issue Date
2007
MeSH
Abdominal Fat/diagnostic imaging ; Abdominal Fat/physiology* ; Blood Glucose/metabolism* ; Body Composition/physiology ; Diabetes Mellitus, Type 2/blood ; Diabetes Mellitus, Type 2/drug therapy ; Diabetes Mellitus, Type 2/physiopathology ; Female ; Glycated Hemoglobin A/metabolism ; Humans ; Hypoglycemic Agents/therapeutic use* ; Lipid Metabolism/drug effects ; Male ; Middle Aged ; Regression Analysis ; Rosiglitazone ; Thiazolidinediones/therapeutic use* ; Ultrasonography
Abstract
OBJECTIVE: The goal was to investigate the interrelationships between the hypoglycemic effects of rosiglitazone and the changes in the regional adiposity of type 2 diabetic patients. DESIGN AND METHODS: We added rosiglitazone (4 mg/day) to 173 diabetic patients (111 males and 62 females) already taking a stable dose of conventional antidiabetic medications except for thiazolidinediones. The abdominal fat distribution was assessed by ultrasonography at baseline and 12 weeks later. Using ultrasonographic images, the s.c. and visceral fat thickness (SFT and VFT respectively) were measured. RESULTS: Rosiglitazone treatment for 3 months improved the glycemic control. However, the response to rosiglitazone was no more than 36.4%; the deterioration of the glycemic control was found in 16.8% of subjects. In addition, rosiglitazone treatment significantly increased the body fat mass, especially the s.c. fat. However that did not alter the visceral fat content. The percentage changes in fasting plasma glucose (FPG) and glycated hemoglobin (HbA1c) concentrations after treatment were inversely correlated with the increase in SFT (r=-0.327 and -0.353, P<0.001 respectively) and/or body weight (r=-0.316 and -0.327, P<0.001 respectively). Multiple regression analysis revealed that the improvement in the FPG after rosiglitazone treatment was correlated with the baseline FPG (P<0.001) and the change in the SFT (P=0.019), and the reduction in the HbA1c was related with the baseline FPG (P=0.003) and HbA1c (P<0.001) and the changes in the SFT (P=0.010) or VFT (P=0.013). CONCLUSIONS: The increase in the s.c. fat depot after rosiglitazone treatment may be an independent factor that determines the hypoglycemic efficacy.
Full Text
http://eje-online.org/content/157/2/167.long
DOI
10.1530/EJE-07-0043
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Soo Kyung(김수경)
Kim, Hae Jin(김혜진)
Park, Seok Won(박석원)
Shim, Wan Sub(심완섭)
Ahn, Chul Woo(안철우) ORCID logo https://orcid.org/0000-0003-3733-7486
Lee, Hyun Chul(이현철)
Lim, Sung Kil(임승길)
Cha, Bong Soo(차봉수) ORCID logo https://orcid.org/0000-0003-0542-2854
Hur, Kyu Yeon(허규연)
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/95985
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse